Shipra G.

Shipra G. has extensive work experience in various scientific and research roles. Shipra is currently working at Lyell Immunopharma as the Head of Analytical Development, a position they have held since March 2022. Prior to this role, they served as the Associate Director and Senior Scientist - Cell Analytics Team Lead at Lyell Immunopharma.

Before joining Lyell Immunopharma, Shipra G. worked at Aptevo Therapeutics Inc as a Senior Scientist from August 2018 to October 2019. In this role, they led biomarker assay development and managed translational/ PD activities at a CRO for a phase 1 clinical trial.

Shipra also gained experience as a Senior Scientist at SNBL USA, Ltd. from November 2015 to July 2018. In this role, they contributed to scientific research and development.

Shipra G.'s earlier experience includes working at the Benaroya Research Institute at Virginia Mason as a Staff Scientist and Sr. Post-doctoral Research Associate. Shipra led collaborative studies with biotech/pharma partners to study T cells in autoimmune diseases and conducted studies on regulatory T-cell therapy for Type 1 Diabetes.

Shipra began their career as a Post-doctoral Research Fellow at Harvard Medical School, where they focused on the role of regulatory T cells in allo-graft rejection. Shipra also worked as a Post-doctoral Research Fellow at IPF Pharmaceuticals GmbH, conducting research under the mentorship of W. G. Forssmann.

Overall, Shipra G. has an extensive background in scientific research and has held various leadership positions in analytical development, translational activities, and cell analytics.

Shipra G. completed their education in a chronological sequence. From 1998 to 2001, they pursued a Bachelor of Science degree in Human Biology with a major in Biochemistry at the All India Institute of Medical Sciences. Following this, they attended the All India Institute of Medical Sciences from 2001 to 2003, where they obtained a Master's in Biotechnology. Shipra G. then enrolled at Hannover Medical School from 2003 to 2006, successfully completing their Ph.D. in Molecular Medicine with a specialization in Immunology. There is no available information regarding their earliest education.